Raza Ali, Author at Cancer Research UK Cambridge Institute

Junior Group Leader

Research Group Home Page:: Ali Group

Work address:: Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE

Publications:: Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome

E-pub date: 01 Jul 2020; Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer

E-pub date: 01 Feb 2020; The single-cell pathology landscape of breast cancer.

E-pub date: 31 Dec 2019; The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

E-pub date: 30 Apr 2019; Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

E-pub date: 31 Mar 2019; Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

E-pub date: 28 Feb 2019; Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study

E-pub date: 01 Feb 2019; Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.

E-pub date: 31 Jul 2018; Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.

E-pub date: 31 May 2018; Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

E-pub date: 07 Mar 2018; Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.

E-pub date: 20 Sep 2017; Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

E-pub date: 01 Aug 2017; Corrigendum: p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.

E-pub date: 01 Aug 2017; TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.

E-pub date: 14 Mar 2017; Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival.

E-pub date: 01 Feb 2017; Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.

E-pub date: 31 Dec 2016; p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.

E-pub date: 22 Dec 2016; The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.

E-pub date: 01 Dec 2016; Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

E-pub date: 18 Oct 2016; High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium.

E-pub date: 31 Jul 2016; Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays.

E-pub date: 31 Mar 2016; Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.

E-pub date: 16 Feb 2016; Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.

E-pub date: 02 Feb 2016; Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

E-pub date: 05 Jan 2016; Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

E-pub date: 04 Nov 2015; PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.

E-pub date: 31 Jul 2015; Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer.

E-pub date: 31 Jul 2015; Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.

E-pub date: 02 Jul 2015; Prognostic and predictive value of PDL1 expression in breast cancer.

E-pub date: 10 Mar 2015; Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

E-pub date: 31 Jan 2015; BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

E-pub date: 09 Jan 2015; Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer.

E-pub date: 03 Dec 2014; Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

E-pub date: 31 Aug 2014; Genome-driven integrated classification of breast cancer validated in over 7,500 samples.

E-pub date: 28 Aug 2014; CEBPD (C/EBP delta) acts as a tumor suppressor in hormone receptor positive breast cancer cells and may serve as biomarker to predict the need for adjuvant therapy

E-pub date: 31 Mar 2013; Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

E-pub date: 21 Feb 2013; Astronomical algorithms for automated analysis of tissue protein expression in breast cancer.

E-pub date: 19 Feb 2013; Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling (Science Translational Medicine (2012) 4, (161er6))

E-pub date: 31 Oct 2012; Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

E-pub date: 24 Oct 2012; Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue.

E-pub date: 31 Jul 2012; Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

E-pub date: 22 May 2012; A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

E-pub date: 31 Jan 2012; Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

E-pub date: 04 Jan 2012; Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance.

E-pub date: 31 Aug 2011; ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.

E-pub date: 31 Mar 2011; Introducing, OncoTarget

E-pub date: 30 Apr 2010; Show all Hide all

Research Integrity Conflict of Interest Disclosure:

Last revised:: –

No items to report

Disclosure guidelines

Raza Ali

Junior Group Leader

Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome

Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer

The single-cell pathology landscape of breast cancer.

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study

Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

Corrigendum: p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.

Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival.

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.

p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.

The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.

Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium.

Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays.

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.

Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer.

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.

Prognostic and predictive value of PDL1 expression in breast cancer.

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer.

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Genome-driven integrated classification of breast cancer validated in over 7,500 samples.

CEBPD (C/EBP delta) acts as a tumor suppressor in hormone receptor positive breast cancer cells and may serve as biomarker to predict the need for adjuvant therapy

Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

Astronomical algorithms for automated analysis of tissue protein expression in breast cancer.

Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling (Science Translational Medicine (2012) 4, (161er6))

Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue.

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance.

ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.

Introducing, OncoTarget

Tweets

CRUK CI staff links

Contact CRUK CI

Useful links

Connect with us

Study at Cambridge

About the University

Research at Cambridge

This Site Uses Cookies